KEGG enrichment analysis (Figure 1E) revealed that the key targets of ISL that antagonise CRC were mainly concentrated in the oestrogen signalling pathway, TNF (tumour-necrosis-factor) signalling pathway, PI3K/AKT (phosphatidylinositol-3-kinase/protein kinase) signalling pathway and other classical signalling pathways. The gene discussed is AKT1; the disease is colorectal carcinoma.